title: Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
abstract: Sterile perforated polyethylene spheres (wiffle golf balls) were implanted s.c. in beagle dogs. A local inflammatory reaction was elicited within the spheres by injecting carrageenan. Changes in leukocyte count, prostaglandin E2, thromboxane B2 and leukotriene B4 levels were monitored in fluid samples collected over a 24-hr period. Blood samples were also collected at various time points and analyzed for prostaglandin E2 and leukotriene B4 production after ex vivo calcium ionophore treatment. Effects of standard antiinflammatory agents (aspirin, indomethacin, dexamethasone, tenidap and zileuton) and newer cyclooxygenase-2 (COX-2) selective agents (nimesulide, nabumetone and SC-58125) were determined after oral administration. Ex vivo inhibition of cyclooxygenase product synthesis (prostaglandin E2, thromboxane B2) in whole blood was used as an indicator of activity for the constitutive COX-1 isoform, although inhibition of the synthesis of these mediators in the chamber exudate during an inflammatory process is believed to represent COX-2 inhibition. Treatment effects on leukotriene B4 production were also determined both ex vivo in whole blood and in the fluid. All of the compounds tested, except aspirin, inhibited leukocyte infiltration into the fluid exudate. Inhibitors that exert their effects on both isozymes of cyclooxygenase attenuate production of cyclooxygenase metabolites in both the inflammatory exudate and in peripheral blood ex vivo, although COX-2 selective inhibitors only demonstrated activity in the exudate. A 5-lipoxygenase inhibitor (zileuton), a corticosteroid (dexamethasone) and a dual COX-2 selective/5-lipoxygenase inhibitor (RWJ 63556) had similar profiles in that they all inhibited cell infiltration and eicosanoid production in the fluid and also attenuated leukotriene B4 production in both the fluid and blood.
authors.affiliation: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kirchner
authors.forename: D C
authors.initials: DC
authors.lastname: Argentieri
authors.forename: A G
authors.initials: AG
authors.lastname: Barbone
authors.forename: M
authors.initials: M
authors.lastname: Singer
authors.forename: M
authors.initials: M
authors.lastname: Steber
authors.forename: J
authors.initials: J
authors.lastname: Ansell
authors.forename: S A
authors.initials: SA
authors.lastname: Beers
authors.forename: M P
authors.initials: MP
authors.lastname: Wachter
authors.forename: W
authors.initials: W
authors.lastname: Wu
authors.forename: E
authors.initials: E
authors.lastname: Malloy
authors.forename: A
authors.initials: A
authors.lastname: Stewart
authors.forename: D M
authors.initials: DM
authors.lastname: Ritchie
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D002351:Carrageenan / Q000633:toxicity; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D005069:Evaluation Studies as Topic; D005260:Female; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D007975:Leukotriene B4 / Q000097:blood; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D013876:Thiophenes / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; C107693:RWJ 63556; D013449:Sulfonamides; D013876:Thiophenes; D007975:Leukotriene B4; D002351:Carrageenan